arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Sana Biotechnology, Inc.

SANA
$3.08 ▼ -0.25 (-7.51%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
28 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

Sana Biotechnology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $910.7M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -33.4%
FCF / Share $-0.12
Trailing P/E
Price / Book 6.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-47.21M
↑ +4.4%
FCF / Share Free cash flow per share
$-0.12
↑ +14.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
5
Cash Quality
44

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 28 quarters